Ari Kirshenbaum, Ph.D.
Ari
Kirshenbaum
Senior Behavioral Scientist, Innovation
Ari Kirshenbaum, Ph.D., is primarily involved in behavioral-health, public-safety, and policy research at AHP; current projects include the public-health ramifications of opioid and cannabis use, addressing national shortages in organs available for transplant, mental health and social support of cancer survivors, and work with the National Institute of Justice.
Dr. Kirshenbaum has over 20 years of research experience in psychopharmacology and, as a principal investigator, received over a million dollars of grant funding from the National Institutes of Health and the National Science Foundation for experimental work in substance dependence. He is Professor Emeritus (Saint Michael’s College), and has published papers on a range of topics, including medical and legal ethics, toxicology, neurobiology, comparative psychology, and behavioral economics. He has extensive expertise in nicotine science, particularly with e-cigarettes, and in implementing harm-reduction and treatment approaches to drug use. He also co-founded a company that developed patented digital technologies to address drug-impaired motor-vehicle operation and served as the Chief Science Officer; given that experience, he now trains legal and law-enforcement professionals about the effects of drugs on behavior and physiology.
Dr. Kirshenbaum received his undergraduate degree from the University of Colorado (B.A.) and graduate degrees (M.A. & Ph.D.) from the University of Montana. He held post-doctoral appointments at NASA Ames Research Center and the University of Vermont, College of Medicine.
